Ceftazidime as Prophylactic Treatment in Renal Stone Surgery

REFERENCES

• Adam D, Reichart B, Williams KJ. Penetration of ceftazidime into human tissue in patients undergoing cardiac surgery. J Antimicrob Chemother 1983; 12 (Suppl A): 269–273.
   PubMedGoogle Scholar
• Alestig K, Trollfors B, Andersson R, Olaison L, Suurküla M, Norrby SR. Ceftazidime and renal function. J Antimicrob Chemother 1984; 13: 177–181.
   PubMed Web of Science ®Google Scholar
• Boyce WH. Surgery of urinary calculi in perspective. Surgery of stone disease. Urol Clin North Am 1983; 10 (4): 585–594.
   PubMed Web of Science ®Google Scholar
• Cars O, Ögren S. A microtechnique for the determination of antibiotics in muscle. J Antimicrob Chemother 1981; 8: 39–48.
   PubMed Web of Science ®Google Scholar
• Cars O, Ögren S. Antibiotic tissue concentrations: Methodological aspects and interpretation of results. Scand J Infect Dis 1985; Suppl 44: 7–15.
   Google Scholar
• Chaussy C, Schmiedt E, Jocham D, Schüller J, Brandl H, Liedl B. Extracorporeal shock-wave lithotripsy (ESWL) for treatment of urolithiasis. Urology 1984; Suppl 23: 59.
   Google Scholar
• Chisholm GD. Antimicrobial prophylaxis in urology and transplantation. World J Surg 1982; 6: 281–291.
   PubMed Web of Science ®Google Scholar
• Cox CE. A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections. J Antimicrob Chemother 1983; 12 (Suppl A): 47–52.
   PubMedGoogle Scholar
• Von Degen J, Ringwelski L, Maier-Lenz H. Konzentration von Cefadroxil im Nierengewebe und Serum nach oraler Applikation bei Patienten mit normaler und eingeschränkter Nierenfunktion. Arzneim-Forsch 1983; 33 (9): 1339–1342.
   PubMedGoogle Scholar
• Diakos GK, Kosinides J, Stathakis Ch, Giamarellou H, Douzinas E, Kastanakis S, Papathanassiou B. Ceftazidime: therapeutic results in various infections and kinetic studies. J Antimicrob Chemother 1981; 8 (Suppl B): 331–337.
   PubMedGoogle Scholar
• Ericsson HM, Sherris J. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Path Microbiol Scand (B), 1971; Suppl 217.
   Google Scholar
• Eron LJ, Goldenburg RI, Park CH, Perez DM. Ceftazidime therapy of serious bacterial infections. Antimicrob Ag Chemother 1983; 23: 236–241.
   PubMed Web of Science ®Google Scholar
• Fowler JEJr. Bacteriology of branched renal calculi and accompanying urinary tract infection. J Urol 1984; 131: 213–215.
   PubMed Web of Science ®Google Scholar
• Gentry LO, Douthit MB, Childs SJ, Madsen PO. A random comparative trial of 0.25, 0.5 and 1.0 g ceftazidime twice daily in urinary tract infection. J Antimicrob Chemother 1983; 12 (Suppl A): 53–57.
   PubMedGoogle Scholar
• Gozzard DI, Geddes AM, Farrell ID, Eykyn SJ, Phillips I, Wise R, Brown RM. Ceftazidime—A new extended-spectrum cephalosporin. Lancet 1982; 22: 1152–1156.
   Google Scholar
• Grabe M, Andersson K-E, Forsgren A, Hellsten S. Concentrations of cefotaxime in serum, urine and tissues of urological patients. Infection 1981; 3: 154–158.
   Google Scholar
• Griffith DP. Struvite stones. Kidney Int 1978; 13: 372–382.
   PubMed Web of Science ®Google Scholar
• Griffith DP, Musher DM, Itin C. Urease. The primary cause of infection-induced urinary stones. Invest Urol 1976; 13 (5): 346–350.
   PubMedGoogle Scholar
• Hellström J. The significance of staphylococci in the development and treatment of renal and ureteral stones. Br J Urol 1938; 10: 348–372.
   Google Scholar
• Hoffstedt B, Walder M. Penetration of ceftazidime into extracellular fluid in patients. J Antimicrob Chemother 1981; 8 (Suppl B): 289–292.
   PubMedGoogle Scholar
• Holmgren K, Backman U, Danielson BG, Fellström B, Ljunghall S, Wikström B. Urinary tract infections and urinary calculi. To be published.
   Google Scholar
• Knothe H, Oette GA. The in vitro activity of ceftazidime against clinically important pathogens. J Antimicrob Chemother 1981; 8 (Suppl B): 33.
   PubMedGoogle Scholar
• Lewi HJE, White A, Hutchinson AG, Scott R. The bacteriology of the urine and renal calculi. Urol Res 1984; 12: 107–109.
   PubMedGoogle Scholar
• Lundbergh P, Jarstrand C, Morfeldt-Månsson L, Weiland O. Ceftazidime in septicaemia. J Antimicrob Chemother 1983; 12 (Suppl A): 199–205.
   PubMedGoogle Scholar
• Mondorf AW, Heynold FT, Schreiberich JE, Hess H, Schoeppe W. Assessment of the nephrotoxic potential of ceftazidime and a ceftazidime/tobramycine combination in volunteers. Infection 1983; II (Suppl I): 57–61.
   Google Scholar
• Naber KG. Renal lymph concentrations of antibiotics. Scand J Infect Dis 1978; (Suppl 14): 164–165.
   Google Scholar
• Nemoy NJ, Stamey TA. Surgical, bacteriological and biochemical management of “infection stones”. JAMA 1971; 215: 1470–1476.
   PubMed Web of Science ®Google Scholar
• de la Pena A, de la Pena E. Case report illustrating brief period of time necessary to formation of large staghorn renal calculus. J Urol 1944; 52: 108.
   Google Scholar
• Phillips I, Varren G, Shannon K, King A, Hanslo D. Ceftazidime: in vitro antimicrobial activity and susceptibility to beta-lactamase compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics. J Antimicrob Chemother 1981; 8 (Suppl B): 23.
   PubMedGoogle Scholar
• Reilly JT, Brada M, Bellingham AJ, Hart CA, Bennet C. Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients. J Antimicrob Chemother 1983; 12 (Suppl A): 89–92.
   PubMedGoogle Scholar
• Rocha H, Santos LCS. Relapse of urinary tract infection in the presence of urinary tract calculi: The role of bacteria within the calculi. J Med Microbiol 1969; 2: 372–376.
   PubMed Web of Science ®Google Scholar
• Ryan DM, Cars O. Antibiotic assays in muscle: Are conventional tissue levels misleading as indicator of the antibacterial activity. Scand J Infect 1980; 12: 302–309.
   Google Scholar
• Ryan MD, Cars O. A problem in the interpretation of β-lactam antibiotic levels in tissues. J Antimicrob Chemother 1983; 12: 281–284.
   PubMed Web of Science ®Google Scholar
• Segura JW. Endourology. J Urol 1984; 132: 1079–1084.
   PubMed Web of Science ®Google Scholar
• Silverman DE, Stamey TA. Management of infection stones: The Stanford experience. Medicine 1983; 62: 44–51.
   PubMed Web of Science ®Google Scholar
• Singh M, Chapman R, Tresidder GC, Blandy J. The fate of the unoperated staghorn calculus. Br J Urol 1973; 45: 581–585.
   PubMedGoogle Scholar
• Stamey TA. The diagnosis, localization, and classification of urinary infections. In: Pathogenesis and Treatment of Urinary Tract Infections. Williams and Wilkins Co, Baltimore 1980: 1–51.
   Google Scholar
• Thonus IP, Kort WJ, Otte CJJ, Fontijne P, Michel MF. Intrarenal distribution of ampicillin in the healthy and the infected rat kidney: a comparison of methods. J Pharmacol Methods 1982; 8: 241–253.
   PubMedGoogle Scholar
• Whelton A, Sapir DG, Carter GG, Kramer J, Walker WG. Intrarenal distribution of penicillin, cephalothin, ampicillin and oxytetracycline during various states of hydration. J Pharmacol Exp Therap 1971; 179: 419–428.
   PubMed Web of Science ®Google Scholar
• Whelton A, Walker WG. An approach to the interpretation of drug concentration in the kidney. Johns Hopkins Med J 1978; 142: 8–14.
   PubMedGoogle Scholar
• Whelton A, Stout RL. An overview of antibiotic tissue penetration. In: Ristuccia AM, Cunha BA, eds. Antimicrobial therapy. New York: Raven Press, 1984: 365–378.
   Google Scholar
• Wiese R, Armstrong GC, Browh RM, Andrew JM. The pharmacokinetic and tissue penetration of ceftazidime and cefamandole in healthy volunteers. J Antimicrob Chemother 1981; 8 (Suppl B): 277–82.
   Google Scholar
• Wolgast M. Renal interstitium and lymphatics. In: Seldin DW, Giebisch G, eds. The kidney. Physiology and pathophysiology. New York: Raven Press, 1985: 497–517.
   Google Scholar